Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology

Three Years On, Strategy Under CEO O’Day Is Unchanged

Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.  

Gilead headquarters in Foster City, CA
Gilead reports Q4 2022 earnings on 2 February • Source: Shutterstock

Ever since CEO Daniel O’Day took the helm and brought in new commercial and research leadership more than three years ago, Gilead Sciences, Inc. has made the case that it would maintain its dominance in HIV while investing to diversify and grow its revenue base by adding high-value cancer drugs to its portfolio. Gilead has encountered skepticism from investors along the way, but the strategy is unchanged, and management insists that is making progress.

Chief commercial officer Johanna Mercier noted in an interview with Scrip during the recent J.P. Morgan Healthcare Conference that “there's...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By 

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.